Enanta Pharmaceuticals (ENTA) Free Cash Flow (2016 - 2025)
Enanta Pharmaceuticals filings provide 14 years of Free Cash Flow readings, the most recent being -$11.8 million for Q4 2025.
- On a quarterly basis, Free Cash Flow rose 53.64% to -$11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.6 million, a 93.38% increase, with the full-year FY2025 number at -$19.3 million, up 77.16% from a year prior.
- Free Cash Flow hit -$11.8 million in Q4 2025 for Enanta Pharmaceuticals, down from -$5.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $27.4 million in Q2 2025 to a low of -$38.8 million in Q4 2022.
- Median Free Cash Flow over the past 5 years was -$21.5 million (2021), compared with a mean of -$18.5 million.
- Biggest five-year swings in Free Cash Flow: crashed 640.28% in 2021 and later surged 228.5% in 2025.
- Enanta Pharmaceuticals' Free Cash Flow stood at -$13.3 million in 2021, then plummeted by 191.33% to -$38.8 million in 2022, then surged by 33.56% to -$25.8 million in 2023, then grew by 0.89% to -$25.5 million in 2024, then skyrocketed by 53.64% to -$11.8 million in 2025.
- The last three reported values for Free Cash Flow were -$11.8 million (Q4 2025), -$5.1 million (Q3 2025), and $27.4 million (Q2 2025) per Business Quant data.